Abstract Details

Title A Cross-Sectional Survey Evaluating Cladribine Tablets Treatment Patterns Among Patients with Multiple Sclerosis Across the US Enrolled in the MS LifeLines Patient Support Program

Topic Multiple Sclerosis

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 340

Objective To better understand patterns of cladribine tablets treatment among patients with multiple sclerosis (MS) enrolled in the MS LifeLines patient-support program.

Background Real-world evidence for cladribine tablets in patients with MS is emerging.

Design/Methods Enrollees from MS LifeLines were invited to participate in an internet-based survey. Participants were included if they self-reported physician-diagnosed relapsing MS, initiated cladribine tablets, and aged ≥18 years. Information collected included demographics, clinical characteristics, MS treatment/disease history, prior disease-modifying therapies (DMTs), and cladribine tablets treatment patterns. Findings were analyzed descriptively.

Results Among 616 patients initiating cladribine tablets and completing the survey from May 12-July 2, 2021, mean (SD) age was 47.8 (11.9); 78.6% female; 75.0% non-Hispanic White/9.9% non-Hispanic Black/7.6% Hispanic; and mean (SD) Charlson Comorbidity Index 0.40 (0.88). Mean (SD) DMTs taken since MS diagnosis was 3.6 (1.9) and 49.2% experienced a relapse in the prior year. Switches to cladribine tablets occurred from other oral (38.4%), infusion (25.9%), and self-injectable (22.1%) DMTs. Reasons for initiating cladribine tablets included doctor recommendation (71.6%), not an injection/infusion/daily pill (49.8%), effective in reducing relapses (49.5%), effective in reducing disability progression (48.5%), and dosing schedule (43.5%). Most patients were partway through the 2-year treatment regimen. Nearly all completed or were planning to complete their currently initiated treatment cycle, and very few required a switch to another DMT: Year 1, 1^st cycle (n=616; 100% initiated; 98.4% completed; 0.8% switched), Year 1, 2^nd cycle (n=544; 88.3% initiated; 99.1% completed; 1.1% switched), Year 2, 1^st cycle (n=226; 36.7% initiated; 100% completed; 0% switched), and Year 2, 2^nd cycle (n=198; 32.1% initiated; 99.5% completed; 1.0% switched). Of the 13 patients from the total cohort who switched to another DMT (2.1%), 46.2% switched to infusions, 30.8% switched to orals, and 23.1% switched to self-injectables.

Conclusions The insights gained provide a better understanding of the real-world treatment patterns of cladribine tablets.

Authors/Disclosures
Jacqueline A. Nicholas, MD (OhioHealth Riverside Methodist Hospital) PRESENTER	Dr. Nicholas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Nicholas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Nicholas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Nicholas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squib. Dr. Nicholas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Nicholas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Nicholas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Greenwich Biosciences. Dr. Nicholas has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Nicholas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Nicholas has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for EMD Serono. Dr. Nicholas has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Nicholas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Nicholas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Vielo Bio. Dr. Nicholas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Nicholas has received research support from Novartis. The institution of Dr. Nicholas has received research support from Biogen. The institution of Dr. Nicholas has received research support from Genentech. The institution of Dr. Nicholas has received research support from PCORI. Dr. Nicholas has a non-compensated relationship as a Physician with National MS Society that is relevant to AAN interests or activities. Dr. Nicholas has a non-compensated relationship as a Physician with Siegal Rare Neuroimmune Association that is relevant to AAN interests or activities.
	No disclosure on file
	No disclosure on file
Lori Lebson	Lori Lebson has nothing to disclose.
	No disclosure on file
Amy L. Phillips, PharmD (EMD Serono)	Amy L. Phillips, PharmD has received personal compensation for serving as an employee of EMD Serono, Inc.

��ɫ��

��ɫ��